BIT 225

Drug Profile

BIT 225

Alternative Names: BIT-225

Latest Information Update: 22 Feb 2017

Price : $50

At a glance

  • Originator Biotron
  • Class Antivirals; Guanidines; Naphthalenes; Pyrazoles; Small molecules
  • Mechanism of Action Hepatitis C virus p7 protein inhibitors; Hepatitis C virus replication inhibitors; HIV replication inhibitors; Human immunodeficiency virus 1 vpu protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Hepatitis C

Highest Development Phases

  • Phase II Hepatitis C; HIV infections; HIV-1 infections

Most Recent Events

  • 13 Feb 2017 Phase-II clinical trials in HIV-1 infections (Treatment-naive, Combination therapy) in Thailand (PO, Capsule) (ACTRN12617000025336)
  • 03 Dec 2015 Biotron plans a phase II trial for HIV infections
  • 30 Sep 2015 BIT 225 is available for licensing as of 30 Sep 2015. http://www.biotron.com.au/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top